Enovis (NYSE:ENOV) Shares Down 6.4% – Time to Sell?

Shares of Enovis Corporation (NYSE:ENOV) were down 6.4% during mid-day trading on Tuesday . The stock traded as low as $22.87 and last traded at $23.0210. Approximately 184,825 shares traded hands during trading, a decline of 83% from the average daily volume of 1,071,094 shares. The stock had previously closed at $24.59.

Analyst Ratings Changes

Several research firms recently weighed in on ENOV. UBS Group restated a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. BTIG Research raised their price objective on shares of Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Wells Fargo & Company decreased their price objective on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average target price of $41.29.

Enovis Stock Down 10.7%

The firm’s 50 day moving average is $25.66 and its two-hundred day moving average is $24.28. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -1.15 and a beta of 1.34.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders acquired 3,200 shares of company stock valued at $69,864. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Institutional investors have recently added to or reduced their stakes in the business. Arax Advisory Partners acquired a new position in Enovis during the 4th quarter valued at approximately $29,000. EverSource Wealth Advisors LLC increased its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Allworth Financial LP purchased a new stake in Enovis in the 2nd quarter worth $36,000. Danske Bank A S bought a new position in Enovis during the 3rd quarter worth $64,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Enovis in the 2nd quarter worth about $48,000. 98.45% of the stock is currently owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.